טוען...
LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma
Neratinib is an orally available tyrosine kinase inhibitor targeting HER2 (ERBB2) and EGFR (ERBB). It is being clinically evaluated for the treatment of breast and other solid tumors types as a single agent or in combination with other chemotherapies. In support of several phase I/II clinical trials...
שמור ב:
| הוצא לאור ב: | J Pharm Biomed Anal |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5183482/ https://ncbi.nlm.nih.gov/pubmed/27907855 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jpba.2016.11.035 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|